ART, weight changes and obesity: results from CASCADE cohort
16 September 2024. Related: Side effects, Lipodystrophy and metabolic complications.
Side effects
Semaglutide in people with HIV: reduces both central and peripheral fat worsening lipoatrophy
27 July 2024. Related: Side effects, Lipodystrophy and metabolic complications.
Drug resistance or side effects might limit ART in up to 1 in 10 people living with HIV
2 May 2024. Related: Antiretrovirals, Treatment strategies, Side effects, Drug resistance.
UK surveys on access to New-Fill for facial lipoatrophy
1 October 2023. Related: Side effects, Lipodystrophy and metabolic complications.
>10% weight gain during first two years of ART linked to double the risk of cardiometabolic disease
1 October 2023. Related: Side effects, Lipodystrophy and metabolic complications.
Altered kidney function associated with alcohol and cannabis use by women living with HIV
1 October 2023. Related: Side effects.
IAS 2023: Metabolic and weight changes using GLP-1 agonists in people living with HIV: need for more data
1 September 2023. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
ART-associated hypertension can be successfully treated in African settings
1 August 2023. Related: Conference reports, Side effects, Coinfections and complications.
Overview of weight gain, integrase inhibitors and ART
1 June 2023. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Selected webcasts from BHIVA 2023
1 June 2023. Related: Conference reports, Treatment strategies, Side effects, Lipodystrophy and metabolic complications.
CROI 2023: Bone density profiles for CAB-LA vs TDF/FTC oral PrEP in young adults
10 March 2023. Related: Conference reports, Side effects, HIV prevention and transmission.
AIDS 2022: Gender-affirming hormones, weight gain and ART
3 October 2022. Related: Conference reports, PK and drug interactions, Side effects.
INSTIs and cardiovascular events in the RESPOND cohort: early increase at six months normalises after two years
1 July 2022. Related: Side effects, Lipodystrophy and metabolic complications.
Weight changes on ART and how to lose weight successfully
1 June 2021. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications, Nutrition.
NICE guidelines on management of chronic pain: exercise but not opiods
3 May 2021. Related: Guidelines, Side effects, Coinfections and complications.
Chronic kidney disease (CKD) in HIV positive people linked to time with low CD4 count: partly reversible after effective ART
12 March 2021. Related: Side effects, Coinfections and complications.
Weight gain with dolutegravir-based ART in Nigerian cohort
14 October 2020. Related: Conference reports, Side effects.
Weight gain with integrase inhibitors and TAF: three reports from AIDS 2020
28 August 2020. Related: Conference reports, Side effects.
Dolutegravir associated with weight gain in African ART programmes: findings from AFRICOS
22 July 2020. Related: Conference reports, Side effects.
Obesity linked to dolutegravir, especially with TAF, could increase risk of adverse pregnancy outcomes
22 July 2020. Related: Conference reports, Women's health, Pregnancy, Side effects.
Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial
17 April 2020. Related: Conference reports, Side effects.
Dolutegravir associated with hyperglycaemia in people switching first-line ART in Uganda
1 April 2020. Related: Side effects.
Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial
12 March 2020. Related: Conference reports, Side effects.
Postpartum weight gain is higher with dolutegravir- compared with efavirenz-based ART among African women
12 March 2020. Related: Conference reports, Pregnancy, Side effects.
Weight changes with doravirine-based first line therapy
13 December 2019. Related: Conference reports, Antiretrovirals, Side effects.
Weight gain and metabolic syndrome with dolutegravir and TAF: results from the ADVANCE trial
15 November 2019. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Switching from TDF to TAF linked to higher BMI and cardio risk
18 October 2019. Related: Conference reports, Antiretrovirals, Side effects.
Possible higher diabetes risk with raltegravir or PIs than NNRTIs
18 October 2019. Related: Conference reports, Antiretrovirals, Side effects.
Greater weight gain with INSTI-based than non-INSTI-based ART among women in US cohort
30 September 2019. Related: Side effects.
Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study
23 August 2019. Related: Conference reports, Antiretrovirals, Treatment strategies, Side effects.
Type 2 diabetes is often undermanaged in HIV positive people
20 May 2019. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications, Coinfections and complications.
Adopting new US blood pressure targets for HIV positive people could reduce cardiovascular-related deaths
20 May 2019. Related: Conference reports, Side effects, Coinfections and complications.
INSTI and weight gain: reports from CROI 2019
20 May 2019. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Are integrase inhibitors linked to weight gain? – an evidence review
21 January 2019. Related: Side effects.
Frailty in older HIV positive people: independent associations with serious morbidity and mortality
21 January 2019. Related: Side effects, Coinfections and complications, Ageing and life expectancy.
Cannabis-based products for medicinal use: Guidance to clinicians
13 November 2018. Related: Side effects, Other news.
Efavirenz side effects and other drug-drug interactions are common in Ugandan cohort
29 June 2018. Related: Conference reports, PK and drug interactions, Side effects.
BHIVA statement on potential safety signal in infants born to women conceiving on dolutegravir
8 June 2018. Related: Treatment alerts, Pregnancy, Side effects.
Boosted darunavir is associated with higher cardiovascular risk in D:A:D study, but not atazanavir
8 June 2018. Related: Side effects, Lipodystrophy and metabolic complications.
Reducing risk of myocardial infarction (MI) in HIV positive people
16 April 2018. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications, Coinfections and complications.
Rate of bone loss on ART slows after the first year
30 March 2018. Related: Conference reports, Side effects.
Meta-analysis reports no significant risk of cardiac, IRIS or suicide with dolutegravir
23 February 2018. Related: Side effects.
Studies on dolutegravir and sleep, cardiovascular and CNS side effects, and risk of IRIS
28 November 2017. Related: Conference reports, Side effects.
Effects of the anti-inflammatory antibody canakinumab on heart disease and cancer: implications for HIV?
28 November 2017. Related: Side effects, Coinfections and complications, Basic science and immunology.
Increased frequency and progression of kidney disease in HIV positive people
1 October 2017. Related: Side effects, Coinfections and complications.
Unexpected side effects with generic abacavir – and potential for rare reactions to other generic ARVs
26 June 2017. Related: Treatment alerts, Antiretrovirals, Side effects.
High rates of of undocumented efavirenz-related side effects in Uganda
26 June 2017. Related: Conference reports, Antiretrovirals, Side effects.
Case report of capsulitis with elvitegravir and cobicistat (EVG/c)
26 June 2017. Related: Side effects.
Further reports of CNS-related side effects with dolutegravir
29 November 2016. Related: Conference reports, Side effects.
Fanconi-like lab abnormalities reported with daily PrEP: shows importance of routine kidney monitoring
1 October 2016. Related: Conference reports, Side effects, HIV prevention and transmission.
Bone loss with PrEP in MSM aged 18-24
1 October 2016. Related: Conference reports, Side effects, HIV prevention and transmission.
Neurological side effects with integrase inhibitors cause low rates of discontinuation in clinical practice
1 October 2016. Related: Conference reports, Side effects.
Raltegravir increases waist circumference more than boosted PIs: greater with use of later ART
1 October 2016. Related: Conference reports, Side effects.
Efavirenz associated with suicide risk in analysis from START study
1 August 2016. Related: Conference reports, Side effects.
Persistent HPV infection may be related to tissue type in HIV positive people
1 June 2016. Related: Side effects.
Alcohol risks are higher in HIV positive people and linked to increased mortality
22 March 2016. Related: Side effects.
Renal monitoring in people living with HIV: a new review
1 February 2016. Related: Side effects.
No difference in neuropsychological test results between early and delayed ART in START substudy
1 December 2015. Related: Conference reports, Side effects, Coinfections and complications.
Immediate ART in START linked to greater bone loss over three years
1 December 2015. Related: Conference reports, Side effects.
Doubled hypogonadism rate in middle-aged men with HIV: fat is a factor
1 October 2015. Related: Conference reports, Antiretrovirals, Side effects.
Neurocognitive disorder, persistent inverted CD4:CD8 ratios and immune activation in the CNS
1 October 2015. Related: Side effects.
CMV associated with 50% increased risk of non-AIDS related mortality in HIV positive people
29 January 2015. Related: Side effects, Coinfections and complications.
Impact of smoking on life expectancy in HIV infection
29 January 2015. Related: Side effects, Coinfections and complications.
Suicide not associated with efavirenz use in the D:A:D cohort study
1 December 2014. Related: Conference reports, Antiretrovirals, Side effects.
Gender differences in use of cardiovascular disease-related interventions: D:A:D study
1 December 2014. Related: Conference reports, Treatment strategies, Women's health, Side effects.